Psychopharmacology

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.

Read discussion of bromism, with case studies and background on bromine.

Lithium significantly reduces suicidal ideation and attempts in bipolar and major depressive disorder patients, enhancing long-term treatment outcomes.

Experts discuss the advantages of long-acting injectables in schizophrenia treatment, highlighting improved adherence, reduced relapse risk, and better patient outcomes.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.

Roger S. McIntyre, MD, FRCPC, shares how FDA approval of Caplyta will benefit patients with major depressive disorder

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

Discover the latest insights on ADHD diagnosis and treatment, including new DSM-5 criteria and effective therapeutic strategies for diverse patient needs.

Maciej Wieczorek, MD, discusses CPL'36, a new PDA101 inhibitor with a novel mechanism of action for treatment of schizophrenia.

American psychiatry reexamines its roots in psychopathology, challenging DSM's validity and advocating for a return to understanding mental illness.

New research reveals how Candida albicans in the gut microbiome influences alcohol consumption and aversion, offering insights for treating alcohol use disorder.

Explore the intersection of psychotherapy and pharmacology in treating mood disorders, emphasizing personalized approaches for optimal patient outcomes.

Tony Tamburello, MD, discusses advancements in correctional psychiatry, emphasizing ethical care, complex patient needs, and the role of technology in treatment.

A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain, highlighting the complexity of treatment outcomes.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.